The Rise of US-China Biotech Partnerships: Opportunities and Emerging Challenges

Key Takeaways

• Chinese biotech companies are becoming critical partners to American firms in early-stage drug development.
• MNCs maintain competitive advantages throughout innovative drug lifecycles, particularly in navigating global regulatory frameworks and leveraging resources during commercialization phases.
• US restrictions on bilateral biotech collaborations could limit these growth opportunities and weaken US pharmaceutical MNCs’ competitiveness.